Cortexin vs Semax

Polypeptide bioregulator from bovine cortex; modulates neurotransmitter activity; activates GABA and dopamine systems; reduces excitotoxicity; stimulates neuronal repair

Cortexin is a polypeptide bioregulator derived from porcine cerebral cortex, used clinically in Russia and Eastern Europe as a neuroprotective and nootropic agent for stroke, traumatic brain injury, and chronic cerebrovascular disorders. It contains a complex mixture of tissue-specific neuropeptides, amino acids, and microelements proposed to support neuronal survival, reduce excitotoxic damage, and promote neurotrophic factor expression in injured brain tissue. Russian clinical trials have examined cortexin in acute ischemic stroke rehabilitation and other neurological conditions, with results suggesting potential benefit in functional recovery, though studies are predominantly published in Russian-language journals with limited methodological transparency by international standards. Cortexin is not FDA-approved; it is a licensed prescription drug in Russia and several post-Soviet states, where it has regulatory approval for neurological indications. Cortexin administration: in clinical settings where it is approved, cortexin is administered by intramuscular injection, typically as a 10 mg dose reconstituted in saline or procaine. Clinical courses in Russian practice involve daily injections over 10-day cycles, repeated 1–2 times per year for chronic neurological conditions. This administration pattern is common to several Russian polypeptide bioregulators, including cerebrolysin — another porcine-derived peptide mixture with a broader international clinical trial dataset — and cortagen, a cardiac-focus bioregulator from the same pharmacological class. Cortexin is the cerebral-cortex-specific member of this class; cortagen targets cardiovascular tissue, and thymalin targets thymic/immune tissue. Provider availability for cortexin outside Russia is limited compared to peptides with international regulatory approvals; it is occasionally carried by compounding pharmacies and specialized nootropic suppliers. The PeptideBase cognitive peptides directory lists verified providers who carry neuroprotective peptide compounds.

Semax is believed to upregulate brain-derived neurotrophic factor (BDNF) and other neuroprotective factors, enhancing neuronal survival and synaptic plasticity. It modulates the dopaminergic and serotonergic systems, contributing to its reported effects on mood and focus. Its mechanism of action differs from classical stimulants — it does not act on adrenergic receptors and does not produce typical stimulant tolerance or dependence patterns.

Semax (MEHFPGP) is a synthetic heptapeptide derived from the N-terminal fragment of ACTH(4-7) with a C-terminal Pro-Gly-Pro extension to enhance stability, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a nootropic and neuroprotective agent, and registered in Russia as a pharmaceutical for cognitive disorders, ischemic stroke, and cerebrovascular insufficiency. Semax modulates BDNF and NGF expression in neural tissue, influences dopaminergic, serotonergic, and cholinergic activity, and is proposed to exert neuroprotective effects in ischemic conditions by reducing neuroinflammation and supporting neuronal survival following cerebrovascular events. Human clinical studies published in peer-reviewed Russian neurology journals (Zh Nevrol Psikhiatr Im S.S. Korsakova) — indexed in PubMed — have examined semax in ischemic stroke patients and cerebrovascular insufficiency, reporting improvements in neurological outcomes and cognitive function; these studies document genuine clinical investigation, though no blinded Western RCTs or external replications exist. Semax is approved in Russia for clinical use in ischemic stroke and cognitive disorders; it has no FDA approval and is not approved in any Western jurisdiction, and while the Russian clinical evidence reflects substantial investigational work, the absence of independently conducted Western trials limits confidence in translating the reported findings to broader clinical recommendations. Semax is available in both standard and N-acetyl semax (N-acetyl-Semax) formulations; N-acetyl semax is considered to have enhanced lipophilicity and potentially extended biological activity, though direct comparative clinical data between formulations is limited. Intranasal administration — semax nasal spray — is the primary delivery route in Russian clinical practice and the form used in the published clinical research, offering rapid mucosal absorption and CNS delivery. Semax nasal spray formulations at 0.1% and 1% concentrations have been used in the Russian clinical program for stroke and cognitive disorder indications; subcutaneous injection is more common in international research compound contexts.